– USA, IL – Mead Johnson Nutrition Company (NYSE: MJN) announced that, at its meeting last week, the Board of Directors increased the maximum size of the board from 12 to 13 and appointed Michael A. Sherman as a new director.
Mr. Sherman is the Chief Operating Officer and Chief Financial Officer of Endocyte Inc., a biopharmaceutical company headquartered in West Lafayette, Indiana. He has been Endocyte’s Chief Financial Officer since 2006.
Previously, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company.
Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. He also serves on the Indianapolis Children’s Museum Board of Trustees.
“Mike’s wide-ranging financial expertise, as well as his experience in health-related industries, will add value to Board deliberations and our efforts to support Mead Johnson’s business growth and advance the company’s mission to nourish the world’s children for the best start in life,” said James M. Cornelius, Chairman of the Board.
About Mead Johnson
Mead Johnson, a global leader in pediatric nutrition, develops, manufactures, markets and distributes more than 70 products in over 50 markets worldwide. The company’s mission is to nourish the world’s children for the best start in life. The Mead Johnson name has been associated with science-based pediatric nutrition products for over 100 years. The company’s “Enfa” family of brands, including Enfamil® infant formula, is the world’s leading brand franchise in pediatric nutrition.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.